Clinical trials: sponsored by ImmunityBio, Inc.

COVID-19

A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

• Terminated
• Age: 16 to 80 years
• Phase 2/3
• Results posted

This is a phase 2/3, multicenter, randomized, placebo-controlled, observer-blind study assessing the safety, tolerability, immunogenicity, and efficacy of prophylactic hAd5-S-Fusion+N-ETSD against COVID-19.

Trial name

NCT06022224

Testing

hAd5-S-Fusion+N-ETSD

Where

United States

Volunteers

35 people, healthy volunteers welcome

Sponsor

ImmunityBio, Inc.